The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
First-in-human study of 4SC-205 (AEGIS), a novel oral inhibitor of Eg5 kinesin spindle protein.
Klaus B. Mross
No relevant relationships to disclose
Dirk Scharr
No relevant relationships to disclose
Heike Richly
No relevant relationships to disclose
Annette Frost
No relevant relationships to disclose
Sebastian Bauer
No relevant relationships to disclose
Babett Krauss
Employment or Leadership Position - 4SC
Stock Ownership - 4SC
Rolf Krauss
Employment or Leadership Position - 4SC
Stock Ownership - 4SC
Anna Mais
No relevant relationships to disclose
Bernhard Hauns
Employment or Leadership Position - 4SC
Bernd Hentsch
Employment or Leadership Position - 4SC
Stock Ownership - 4SC
Roland Baumgartner
Employment or Leadership Position - 4SC
Stock Ownership - 4SC
Max E. Scheulen
Consultant or Advisory Role - 4SC